Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vandetanib + dasatinib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Vandetanib + dasatinib is a combination of two small molecule tyrosine kinase inhibitors investigated primarily for the treatment of diffuse intrinsic pontine glioma (DIPG) in pediatric patients. Vandetanib acts as a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR), and RET tyrosine kinases, thereby inhibiting angiogenesis and tumor cell proliferation. Dasatinib is a multi-targeted kinase inhibitor with strong activity against platelet-derived growth factor receptors (PDGFRs) and Src family kinases. The rationale for combining these agents lies in their complementary inhibition of critical signaling pathways involved in glioma pathogenesis—VEGF/VEGFR-mediated angiogenesis and PDGF/PDGFR-driven tumor cell survival and proliferation. This combination has been evaluated in phase I clinical trials during and after radiotherapy for children with newly diagnosed DIPG[1][2][3][4].
- Brand names
- CaprelsaSprycel
- Other names
- vandetanib + dasatinib
02
Targets
VEGFR3 (Vascular endothelial growth factor receptor 3)SFK (SRC family kinases)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFR (PDGFR family)EGFR T790M (Epidermal growth factor receptor T790M mutant)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on vandetanib + dasatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vandetanib + dasatinib.